Sobi Beats 2025 Revenue, Margin Forecasts on Strong Q4 Sales

Event summary

  • Sobi reported full-year 2025 revenue of approximately SEK 28.2 billion, a 15% constant exchange rate (CER) increase.
  • The adjusted EBITA margin reached approximately 40% of revenue, exceeding previous guidance.
  • Q4 sales of Doptelet, Gamifant, and the Haemophilia portfolio were the primary drivers of the outperformance.
  • Sobi previously projected low double-digit CER revenue growth and an adjusted EBITA margin in the mid-to-high 30s percentage range.

The big picture

Sobi's strong 2025 results highlight the potential for specialized biopharma companies focused on rare diseases to generate significant revenue and profitability. The outperformance suggests a favorable market environment and effective execution within Sobi's portfolio, but also underscores the importance of managing growth and maintaining margins in a competitive landscape. The company's SEK 28.2 billion revenue places it as a notable player in the global biopharma sector.

What we're watching

Growth Sustainability
Whether Sobi can maintain the high growth rate observed in Q4 2025, particularly given the reliance on a few key products, will be crucial for future performance.
Margin Pressure
The increased EBITA margin may face pressure if Sobi pursues further expansion or encounters unforeseen cost increases, requiring careful management of operational efficiency.
Guidance Reset
The company's next earnings report on February 5th will be closely watched for a revised full-year 2026 outlook, which will signal management's confidence in the continued momentum.

Related topics

Revenue Growth